Cancer Research Consortium of West Michigan
P: 616.391.1230 | 800.336.6299 | www.crcwm.org

FAST FACTS

Alliance A211601 - EVALUATION OF MAMMOGRAPHIC BREAST DENSITY EFFECT OF ASPIRIN: A COMPANION STUDY TO ALLIANCE STUDY A011502

Eligibility Criteria

1. Patients must be women either concurrently enrolling or previously enrolled to Alliance A011502. Eligible patients may be either pre- or post-menopausal.
2. Patients must either have hormone receptor-negative breast cancer or be ER+ patients who have completed hormone therapy (e.g., tamoxifen, aromatase inhibitors) at least 6 months prior to registration to A011502.
3. Patients must have baseline breast density measurement as defined by one of the following:
   - ≥ 25% breast density, or
   - scattered areas of fibroglandular density, or
   - breast composition category b, c, or d, per BI-RADS 2013
4. Baseline digital screening mammogram (mediolateral [MLO] and craniocaudal [CC] views) taken prior to registration must be available for submission.
   For patients enrolling concurrently with Alliance A011502: Baseline digital screening mammogram must be taken within 8 weeks prior to registration to A211601. If a baseline mammogram within 8 weeks is not available, a new screening mammogram must be performed prior to treatment on Alliance A011502. To receive reimbursement for the cost of this additional mammogram, institutions may submit the A211601 Reimbursement Form, which is available on the Alliance and CTSU web pages.
   For patients enrolling retrospectively: The patient's previous routine mammogram on file must be within 1 year prior to registration to A011502.
5. Contralateral unaffected breast in place (with no prior cancer or radiation, no implants and no plan for breast surgery on contralateral breast over the course of the study). Patients with a prior biopsy on the unaffected breast are eligible.
6. Not pregnant and not nursing.

Schema